Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced the 10 Patient Entrepreneurs selected as finalists for the Lyfebulb and...
UPPSALA, Sweden , Aug. 10, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical Industries Limited ("Sun"). The Notice Letter advises Orexo of Sun's filing of an Abbreviated N...
UPPSALA, Sweden , July 16, 2020 /PRNewswire/ -- Investing in diversification to drive future growth Q2 2020 highlights Total net revenues of SEK 179.1 m (201.2) EBITDA of SEK -9.0 m (60.4), positive EBITDA of SEK 26.5 m (60.4) excluding accelerated DTx US launch ...
FDA's "Enforcement Policy" and Orexo's strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies Preliminary estimated sales potential of USD 420 -650 million for the DTx portfolio five years post launch To enab...
UPPSALA, Sweden , June 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorpt...
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive ...
NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentatio...
NEW YORK , June 22, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 18 th conference are now available for on-demand viewing at VirtualInvestorConferences.com. ...
UPPSALA, Sweden , June 17, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that the Lyfebulb-Orexo Innovation Challenge: Digital Therapeutics for Substanc...
NEW YORK , June 15, 2020 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Global Virtual lnvestor Conference, the leading proprietary investor conference series. Individual investors, institutional investors, advisors and analysts are invited ...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...